Auxilium Pharmaceuticals Announces License Agreement with Vivus for Marketing Rights to STENDRA In US, Canada

Auxilium Pharmaceuticals AUXL announced today the signing of an agreement with VIVUS VVUS providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.  The parties also simultaneously signed a Commercial Supply Agreement pursuant to which VIVUS will be initially responsible for the manufacture and supply of STENDRA to Auxilium. STENDRA is an oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of erectile dysfunction (ED). Under the license, Auxilium will pay VIVUS a one-time license fee of $30 million.  Auxilium may make a $15 million regulatory milestone payment to VIVUS if the FDA approves the STENDRA label to reflect a 15 minute or less onset of action efficacy claim and up to $255 million in potential milestone payments based on the achievement of certain sales targets. VIVUS will also receive royalties on product sales. It is estimated that more than 50 percent of men over 40 years of age experience some degree See full press release